These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
92 related articles for article (PubMed ID: 7593495)
1. Inhibition of ovarian-derived prorenin to angiotensin cascade in the treatment of ovarian hyperstimulation syndrome. Morris RS; Wong IL; Kirkman E; Gentschein E; Paulson RJ Hum Reprod; 1995 Jun; 10(6):1355-8. PubMed ID: 7593495 [TBL] [Abstract][Full Text] [Related]
2. The role of enalapril in the prevention of ovarian hyperstimulation syndrome: a rabbit model. Gul TG; Posaci C; Caliskan S Hum Reprod; 2001 Nov; 16(11):2253-7. PubMed ID: 11679499 [TBL] [Abstract][Full Text] [Related]
3. Effects of angiotensin converting enzyme inhibitor cilazapril and angiotensin II antagonist saralasin in ovarian hyperstimulation syndrome in the rabbit. Sahin Y; Kontaş O; Müderris II; Cankurtaran M Gynecol Endocrinol; 1997 Aug; 11(4):231-6. PubMed ID: 9272418 [TBL] [Abstract][Full Text] [Related]
4. Angiotensin converting enzyme inhibition of the gonadotropin-stimulated rabbit: effect on estradiol production. Morris RS; Wong IL; Paulson RJ J Assist Reprod Genet; 1995 May; 12(5):326-9. PubMed ID: 8520197 [TBL] [Abstract][Full Text] [Related]
5. Comparison of the effects of letrozole and cabergoline on vascular permeability, ovarian diameter, ovarian tissue VEGF levels, and blood PEDF levels, in a rat model of ovarian hyperstimulation syndrome. Şahin N; Apaydın N; Töz E; Sivrikoz ON; Genç M; Turan GA; Cengiz H; Eskicioğlu F Arch Gynecol Obstet; 2016 May; 293(5):1101-6. PubMed ID: 26690356 [TBL] [Abstract][Full Text] [Related]
6. Hemodynamic state and the role of angiotensin II in ovarian hyperstimulation syndrome in the rabbit. Teruel MJ; Carbonell LF; Llanos MC; Parrilla JJ; Abad L; Hernandez I Fertil Steril; 2002 Jun; 77(6):1256-60. PubMed ID: 12057737 [TBL] [Abstract][Full Text] [Related]
7. In vivo intrabursal administration of bioactive lipid sphingosine-1-phosphate enhances vascular integrity in a rat model of ovarian hyperstimulation syndrome. Di Pietro M; Pascuali N; Scotti L; Irusta G; Bas D; May M; Tesone M; Abramovich D; Parborell F Mol Hum Reprod; 2017 Jun; 23(6):417-427. PubMed ID: 28379469 [TBL] [Abstract][Full Text] [Related]
8. GnRHa trigger and individualized luteal phase hCG support according to ovarian response to stimulation: two prospective randomized controlled multi-centre studies in IVF patients. Humaidan P; Polyzos NP; Alsbjerg B; Erb K; Mikkelsen AL; Elbaek HO; Papanikolaou EG; Andersen CY Hum Reprod; 2013 Sep; 28(9):2511-21. PubMed ID: 23753114 [TBL] [Abstract][Full Text] [Related]
9. Prevention of the onset of ovarian hyperstimulation syndrome (OHSS) in the rat after ovulation induction with a low molecular weight agonist of the LH receptor compared with hCG and rec-LH. van de Lagemaat R; Raafs BC; van Koppen C; Timmers CM; Mulders SM; Hanssen RG Endocrinology; 2011 Nov; 152(11):4350-7. PubMed ID: 21896671 [TBL] [Abstract][Full Text] [Related]
10. Everolimus, an mTOR pathway inhibitor, is highly successful on ovarian hyperstimulation syndrome by reducing ovarian weight and progesterone levels: a preclinical experimental randomized controlled study. Kosmas IP; Kitsou C; Lazaros L; Markoula S; Peschos D; Mynbaev O; Tournaye H; Prapas N; Prapas I; Zikopoulos A; Galani V; Georgiou I Gynecol Endocrinol; 2015; 31(9):702-7. PubMed ID: 26172931 [TBL] [Abstract][Full Text] [Related]
11. The role of vascular endothelial growth factor and interleukins in the pathogenesis of severe ovarian hyperstimulation syndrome. Rizk B; Aboulghar M; Smitz J; Ron-El R Hum Reprod Update; 1997; 3(3):255-66. PubMed ID: 9322101 [TBL] [Abstract][Full Text] [Related]
12. A potential novel strategy, inhibition of vasopressin-induced VEGF secretion by relcovaptan, for decreasing the incidence of ovarian hyperstimulation syndrome in the hyperstimulated rat model. Cenksoy C; Cenksoy PO; Erdem O; Sancak B; Gursoy R Eur J Obstet Gynecol Reprod Biol; 2014 Mar; 174():86-90. PubMed ID: 24405730 [TBL] [Abstract][Full Text] [Related]
14. The combination of Everolimus with Verapamil reduces ovarian weight and vascular permeability on ovarian hyperstimulation syndrome: a preclinical experimental randomized controlled study. Kitsou C; Kosmas I; Lazaros L; Tzallas C; Tinelli A; Mynbaev O; Prapas N; Prapas I; Dalkalitsis A; Georgiou I Gynecol Endocrinol; 2016 Nov; 32(11):886-890. PubMed ID: 27223459 [TBL] [Abstract][Full Text] [Related]
15. Montelukast is effective in preventing of ovarian hyperstimulation syndrome; an experimental study. Eskicioğlu F; Turan GA; Sivrikoz ON; Cengiz H; Zafer A; Akan Z; Sahin N; Yilmaz O; Yeşil H; Vatansever S Ginekol Pol; 2015 Aug; 86(8):566-73. PubMed ID: 26492704 [TBL] [Abstract][Full Text] [Related]
16. The effects of resveratrol on ovarian hyperstimulation syndrome in a rat model. Ozgur S; Oktem M; Altinkaya SO; Oktem EO; Cenksoy C; Erdem O; Elbeg S; Helvaci A; Erdem A; Erdem M Taiwan J Obstet Gynecol; 2018 Jun; 57(3):383-388. PubMed ID: 29880170 [TBL] [Abstract][Full Text] [Related]
17. Inhibition of cyclooxygenase-2 (COX-2) by meloxicam decreases the incidence of ovarian hyperstimulation syndrome in a rat model. Quintana R; Kopcow L; Marconi G; Young E; Yovanovich C; Paz DA Fertil Steril; 2008 Oct; 90(4 Suppl):1511-6. PubMed ID: 18166186 [TBL] [Abstract][Full Text] [Related]
18. Dual renin-angiotensin blockage and total embryo cryopreservation is not a risk-free strategy in patients at high risk for ovarian hyperstimulation syndrome. Ata B; Yakin K; Alatas C; Urman B Fertil Steril; 2008 Sep; 90(3):531-6. PubMed ID: 18001715 [TBL] [Abstract][Full Text] [Related]
19. Angiotensin-converting enzyme inhibitor enalapril reduces formation of hypertrophic scars in a rabbit ear wounding model. Uzun H; Bitik O; Hekimoğlu R; Atilla P; Kaykçoğlu AU Plast Reconstr Surg; 2013 Sep; 132(3):361e-371e. PubMed ID: 23985648 [TBL] [Abstract][Full Text] [Related]
20. Comparison of montelukast and cabergoline for prevention of ovarian hyperstimulation syndrome: in an experimental rat model. Akman L; Sahin G; Erbas O; Aktug H; Akdogan A; Goker EN; Taskiran D; Tavmergen E Gynecol Endocrinol; 2015 May; 31(5):369-73. PubMed ID: 25599748 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]